Effect of statins and ezetimibe on the progression of atherosclerosis

Authors: Peter Olexa 1,2
Authors‘ workplace: Klinika gerontológie a geriatrie LF UPJŠ a Leteckej vojenskej nemocnice, a. s., Košice 1;  TOPCARE s. r. o. – privátna kardiologická a interná ambulancia, Košice 2
Published in: AtheroRev 2017; 2(2): 98-104
Category: clinical studies


Recent years have brought a significant amount of new results in the field of atherosclerosis. It is well recognized that low-density lipoprotein cholesterol (LDL-C) lowering therapy is effective for reducing the intensity of atherosclerosis process and even able to regress atherosclerosis. This review presents the current data concerning the efficacy and safety of hypolipidemic treatment with statins in monotherapy and/or in combination with ezetimibe for the depression or even regression of atherosclerotic process in human arteries. Ezetimibe, an inhibitor of the Niemann-Pick C1-Like 1 cholesterol transporter, is a relatively new drug for LDL-C-lowering therapy in addition to statins. However, comparison between an aggressive LDL-C-lowering therapy with a combination of statin and ezetimibe vs. a standard LDL-C-lowering therapy with statin alone was unclear in terms of their effects on stabilization and volume regression of coronary plaque. The PRECISE-IVUS study was aimed at comparing these two types of therapy based on indices of plaque characteristics using intravascular ultrasound. The main aim of this paper was to discuss the results of the PRECISE-IVUS study in comparison to results other similar clinical studies.

Key words:
atherosclerosis, ezetimibe, IMT – intimo-medial thickness, intravascular ultrasonography, LDL-cholesterol, regression


1. Nichols M, Townsend N, Luengo-Fernandez R et al. European Cardiovascular Disease Statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis 2012. ISBN 978–2-9537898–1-2. Dostupné z WWW: <https://www.escardio.org/static_file/Escardio/Press-media/press-releases/2013/EU-cardiovascular-disease-statistics-2012.pdf>.

2. Libby P. How does lipid lowering prevent coronary events? New insights from human imaging trials. Eur Heart J 2015;36(8): 472–474. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu510>.

3. Nicholls SJ, Hsu A, Wolski K et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010; 55(21): 2399–2407. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2010.02.026>.

4. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495–1504.

5. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39): 2999–3058.

6. Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis Current view and future perspective on lipoprotein modification treatment. Neth Heart J 2017; 25(4): 231–242. Dostupné z DOI: <http://dx.doi.org/10.1007/s12471–017–0959–2>.

7. Bots ML, Evans GW, Tegeler CH. Carotid IntimaMedia Thickness Measurements: Relations with Atherosclerosis, Risk of Cardiovascular Disease and Application in Randomized Controlled Trials. Chin Med J (Engl) 2016; 129(2): 215–226. Dostupné z DOI: <http://dx.doi.org/10.4103/0366–6999.173500>.

8. Espeland MA, O’Leary DH, Terry JG et al. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005; 10; 6(1):3.

9. Bots ML, Baldassarre D, Simon A et al. Carotid intimamedia thickness and coronary atherosclerosis: Weak or strong relations? Eur Heart J 2007; 28(4): 398406.

10. Taylor AJ, Bindeman J, Le TP et al. Progression of calcified coronary atherosclerosis: relationship to coronary risk factors and carotid intimamedia thickness. Atherosclerosis 2008; 197(1): 339345.

11. Gronewold J, Bauer M, Lehmann N et al. Coronary artery calcification, intimamedia thickness, and anklebrachial index are complementary stroke predictors. Stroke 2014; 45(9): 2702–2709. Dostupné z DOI: <http://dx.doi.org/10.1161/STROKEAHA.114.005626>.

12. Amato M, Montorsi P, Ravani A et al. Carotid intimamedia thickness by Bmode ultrasound as surrogate of coronary atherosclerosis: Correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. Eur Heart J 2007; 28(17): 20942101.

13. Oh BH, Kaligis RW, Wang Y et al. Survey of atherosclerotic disease in Asian subjects with cardiovascular disease risk factors who were not receiving lipidlowering agents. Int J Cardiol 2013; 168(3): 2761–2766. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2013.03.132>.

14. Amarenco P, Labreuche J, Lavallée P et al. Statins in stroke prevention and carotid atherosclerosis: Systematic review and uptodate metaanalysis. Stroke 2004; 35(12): 2902–2909.

15. Huang Y, Li W, Dong L et al. Effect of statin therapy on the progression of common carotid artery intimamedia thickness: An updated systematic review and metaanalysis of randomized controlled trials. J Atheroscler Thromb 2013; 20(1): 10821.

16. Kotseva K, Wood D, De Backer G et al. [EUROASPIRE Investigators]. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2015; 23(6): 636–648. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487315569401>.

17. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE Study Group: Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373(9667): 929–940. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(09)60330–5>.

18. Kastelein JJP, Akdim F, Stroes ESG et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New Engl J Med 2008; 358(14): 1431–1443. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0800742>. Erratum in N Engl J Med 2008; 358(18): 1977.

19. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? New Engl J Med. 2008; 358(14):1504–1507. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMe0801608>.

20. Fleg JL, Mete M, Howard BV et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008; 52(25): 2198–2205. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.10.031>.

21. Meaney A, Ceballos G, Asbun J, et al. The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study. J Clin Pharmacol 2009; 49(7): 838–847. Dostupné z DOI: <http://dx.doi.org/10.1177/0091270009337011>.

22. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2014; 291(9): 1071–1080.

23. Hiro T, Kimura T, Morimoto T et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] study). J Am Coll Cardiol 2009; 54(4): 293–302. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2009.04.033>.

24. Puri R, Libby P, Nissen SE et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN study. Eur Heart J Cardiovasc Imaging 2014; 15(4): 380–388. Dostupné z DOI: <http://dx.doi.org/10.1093/ehjci/jet251>.

25. Raber L, Taniwaki M, Zaugg S et al. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study, Eur Heart J 2015; 36(8): 490–500. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu373>.

26. Cannon CP, Giugliano RP, Blazing MA et al. Rationale and design of IMPROVE–IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156(5): 826–832. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2008.07.023>.

27. Tsujita K, Sugiyama S, Sumida H et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol 2015; 66(5): 495–507. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.05.065>.

28. Sternberg Z, Chichelli T, Sternberg D et al. Quantitative and qualitative pleiotropic differences between simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects. Atherosclerosis 2013; 231(2):411–420. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2013.09.031>.

29. Munoz-Pacheco P, Ortega-Hernandez A, Miana M et al. Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism. Pharmacol Res 2012; 66(6): 536–543. Dostupné z DOI: <http://dx.doi.org/10.1016/j.phrs.2012.09.005>.

30. Qin L, Yang YB, Yang YX et al. Inhibition of smooth muscle cell proliferation by ezetimibe via the cyclin D1-MAPK pathway. J Pharmacol Sci 2014; 125(3): 283–291.

31. Hussein O, Minasian L, Itzkovich Y et al. Ezetimibe’s effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 2008; 65(5): 637–645. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2125.2007.03080.x>.

Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account